Acadia Pharmaceuticals Inc. develops and commercializes therapies for neurological and rare diseases. Its commercial portfolio includes NUPLAZID (pimavanserin) for hallucinations and delusions associated with Parkinson’s disease psychosis and DAYBUE (trofinetide), including DAYBUE STIX, for Rett syndrome.
Company news commonly covers product revenue from NUPLAZID and DAYBUE, formulation and launch updates for trofinetide, clinical and scientific presentations across neurological disorders, pipeline work in Alzheimer’s disease psychosis, Lewy body dementia psychosis and essential tremor, investor-conference participation, and board or research-and-development leadership changes.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) will present at the Stifel 2020 Virtual Healthcare Conference on November 17, 2020, at 3:20 p.m. ET. The event will be held virtually, and a live webcast of the presentation can be accessed on Acadia's website, with an archived recording available until December 15, 2020. Acadia specializes in neuroscience, having developed the first therapy for hallucinations and delusions related to Parkinson’s disease psychosis, and is involved in various research areas including dementia-related psychosis and schizophrenia.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) reported strong Q3 2020 financial results, with net sales of NUPLAZID reaching $120.6 million, marking a 27% increase year-over-year. The company anticipates a PDUFA date of April 3, 2021, for its supplemental NDA targeting dementia-related psychosis. Despite growth, Acadia posted a net loss of $84.7 million for the quarter, attributed to increased expenses related to the acquisition of CerSci Therapeutics. Cash reserves stood at $644.4 million. Guidance for NUPLAZID sales remains at $430 to $450 million for 2020.
Acadia Pharmaceuticals (Nasdaq: ACAD) will present new analyses of pimavanserin clinical data for dementia-related psychosis at the 13th Clinical Trials on Alzheimer's Disease Conference (CTAD) from November 4-7, 2020. Presentations will cover the impact of pimavanserin on cognition and motor function in neurodegenerative conditions, alongside safety assessments. Notable presentations include findings from the Phase 3 HARMONY Study and a literature review on antipsychotic treatments for dementia-related psychosis. The FDA accepted Acadia's supplemental application for pimavanserin in this indication, with a PDUFA date set for April 3, 2021.
Acadia Pharmaceuticals (ACAD) plans to report its third-quarter financial results on November 4, 2020, after market close. A conference call will follow at 4:30 PM ET to discuss the results. Participants can access the call via various numbers provided for U.S. and international callers. The call will also be available as a live webcast on Acadia's website, which will remain archived until December 2, 2020. Acadia focuses on neuroscience breakthroughs, notably the only approved therapy for Parkinson's disease psychosis, and is exploring treatments for other neuropsychiatric conditions.
Acadia Pharmaceuticals and the Lewy Body Dementia Association have announced a partnership to produce an educational adaptation of the film Robin's Wish. This new version, titled SPARK - Robin Williams and his Battle with Lewy Body Dementia, aims to increase awareness and educate healthcare professionals about Lewy body dementia (LBD), which affects 1.4 million people in the U.S. The film will be available in late October for academic institutions to aid in outreach and education on LBD symptoms and management.